8-K: Silexion Therapeutics Advances SIL-204 for KRAS-Driven Cancers Following Positive Phase 2 Results

Silexion Therapeutics is progressing its lead candidate, SIL-204, for pancreatic cancer treatment, building on promising Phase 2 trial results showing a significant improvement in overall survival.

Summary

• Silexion Therapeutics is a clinical-stage company focused on developing RNAi therapeutics for KRAS-driven cancers.
• Their lead candidate, SIL-204, is an optimized siRNA formulation designed to silence oncogenes and prevent the production of mutated KRAS proteins.
• A Phase 2 trial of their previous candidate, Loder, showed a 9.3-month improvement in overall survival when combined with chemotherapy compared to chemotherapy alone in patients with locally advanced pancreatic cancer (LAPC).
• SIL-204 is designed to have enhanced stability, broader activity, and a new formulation for better delivery compared to Loder.
• The company plans to submit a Clinical Trial Application (CTA) in the EU in the first half of 2025 and initiate a Phase 2/3 trial in the first half of 2026.
• SIL-204 targets KRAS G12D/V mutations, which are present in approximately 74% of pancreatic cancer cases, while current KRAS G12C treatments only address about 1.5% of cases.
• Preclinical studies show that SIL-204 inhibits tumor growth and increases cell death in pancreatic cancer models.
• The company has received positive guidance from the German regulatory agency (BfArM) on the design of their Phase 2/3 trial.

Sentiment

Score: 8

Explanation: The document presents a positive outlook with promising clinical data and a clear development plan for SIL-204. The company has a strong scientific foundation and a clear regulatory path forward. However, the company is still in the development stage and faces risks associated with clinical trials and commercialization.

Positives

• The Phase 2 trial of Loder demonstrated a significant 9.3-month improvement in overall survival for patients with LAPC.
• SIL-204 has shown enhanced stability in human serum compared to previous candidates and other siRNAs on the market.
• SIL-204 has demonstrated broad inhibition across human KRAS mutations at sub-nanomolar concentrations.
• Preclinical studies show that SIL-204 significantly reduces tumor volume and increases necrosis in pancreatic cancer models.
• The company has a clear regulatory path forward with guidance from the German regulatory agency.
• The company has a strong intellectual property portfolio with exclusivity through December 2043 plus extensions.

Negatives

• Silexion is a development-stage company with a limited operating history.
• The company has not generated any revenue from product sales and may never be profitable.
• The approach Silexion is taking to develop RNAi therapeutics for oncology is unproven.
• There is uncertainty regarding market receptiveness to their product candidates and insurance coverage.
• The company may be unable to attract, develop, or retain key personnel.

Risks

• Silexion is a development-stage company and has a limited operating history.
• The company has never generated any revenue from product sales and may never be profitable.
• The approach Silexion is taking to discover and develop novel RNAi therapeutics is unproven for oncology and may never lead to marketable products.
• Silexion does not have experience producing its product candidates at commercial levels, currently has no marketing and sales organization, has an uncertain market receptiveness to its product candidates, and is uncertain as to whether there will be insurance coverage and reimbursement for its potential products.
• Silexion may be unable to attract, develop and/or retain its key personnel or additional employees required for its development and future success.
• There are additional factors relating to the business, operations and financial performance of Silexion that could impact results.

Future Outlook

Silexion plans to advance SIL-204 through Phase 2/3 clinical trials, targeting regulatory approvals and commercialization. They are also exploring other indications for their technology.

Management Comments

• Silexion's management is focused on advancing SIL-204 through clinical trials.
• The company is leveraging the positive results from the Loder Phase 2 trial to improve SIL-204.
• Management believes that SIL-204 has the potential to significantly improve outcomes for patients with KRAS-driven cancers.

Industry Context

The development of targeted therapies for KRAS-driven cancers is a significant area of focus in oncology. Silexion's approach of using siRNA to silence oncogenes at the gene expression level is a novel approach compared to traditional small molecule inhibitors. The company is competing with other companies developing KRAS inhibitors, but their approach is unique in that it targets the mRNA of the mutated KRAS gene.

Comparison to Industry Standards

• The 9.3-month improvement in overall survival observed in the Loder Phase 2 trial is a significant result compared to standard of care chemotherapy alone for LAPC.
• Current KRAS G12C inhibitors, such as sotorasib and adagrasib, target a specific mutation and have shown limited efficacy in pancreatic cancer, while SIL-204 targets a broader range of KRAS mutations.
• The stability of SIL-204 in human serum for over 48 hours is a significant improvement compared to other siRNAs on the market, which typically have a half-life of minutes.
• The intratumor delivery approach of SIL-204 is designed to overcome the limitations of systemic delivery of KRAS inhibitors, which often have low tolerability and limited response rates.

Stakeholder Impact

• Shareholders may benefit from the potential success of SIL-204 and the company's growth.
• Patients with pancreatic cancer may benefit from a new treatment option with improved efficacy.
• Employees may benefit from the company's growth and success.
• The company's success may have a positive impact on the biotechnology industry.

Next Steps

• Submit a Clinical Trial Application (CTA) in the EU in the first half of 2025.
• Initiate a Phase 2/3 trial of SIL-204 in the first half of 2026.
• Conduct toxicology studies for SIL-204.
• Complete GMP production of SIL-204 API and injectable formulation.
• Submit an IND to the FDA.
• Expand the Phase 2/3 trial to the USA and additional EU sites.
• Initiate preclinical studies for SIL-204 in colorectal cancer.

Key Dates

Keywords

KRAS, siRNA, pancreatic cancer, SIL-204, LAPC, oncogene, RNAi, clinical trial, drug development, targeted therapy